531 kidney transplant recipients were studied. BKV-DNA was evaluated using a commercial Real Time PCR Kit (BKV Q-PCR Alert Kit, Nanogen Advanced Diagnostics, Milan, Italy) and VP1 mRNA was quantified by a standardized home made RT-Real Time PCR (1) and then normalized on the number of urinary cells, in order to define VP1 mRNA as a marker of active replication of the virus. Table 1 . Briefly, 45/531 (8.5%) and 68/531 (12.8%) patients were positive to BKV-DNA on serum and on urine, respectively. A diagnosis of BKVAN was placed in two patients. Viral replication, based on VP1 mRNA, was present in 11/531 (2.1%) patients, in particular 5/102 (4.9%) in the first year post-transplantation; two of them (40%) with BKVAN. VP1 mRNA was observed in all cases, except 5, associated with viremia and in all cases with viruria. No significant difference was found between VP1 mRNA in the two patients with nephropathy and those without. Considering receiving operating characteristics, the VP1 mRNA was not higher than viremia, despite combined measurements between viremia (cut-off 16000 copies/ml) and the VP1 mRNA (cut-off >10000 copie/10 3 cells).

